US-based biotech startup Solstice Biologics, which has an exclusive licence with University of California, San Diego, receives $18m series A investment.

Solstice Biologics, a San Diego-based biotech startup which has an exclusive licence for intellectual property covering RNA technologies from the University of California, San Diego (UoCSD), has received $18m in a series A round led by venture firm venBio, with participation from private equity fund Aeris Capital.

It is the first such investment in the firm, which was set up three months ago by professor of cellular and molecular medicine at UoCSD, Steven Dowdy, and Curt Bradshaw, who has more…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?